Lipid nanoparticles (LNPs) and solid lipid nanoparticles (SLNs) have an average diameter between 10 and 1000 nanometers and are among the most clinically advanced non-viral gene delivery systems. They can effectively deliver nucleic acids, overcoming a barrier preventing the development and application of genetic medicines.

Lipid Nanoparticles - our High Pressure Homogenizers

  Easy to scale systems from Lab R&D to production volumes - up to 2000 l/h - that can produce a very high number of doses.

  High-shear processing efficiently creates consistent particle sizes with narrow distributions, increasing product stability and improving processes such as sterilization.

  Industry-leading pressures up to 60,000 psi (4200 bar, 420 MPa).

  Multiple options for temperature control, including pre-heating and rapid post-process cooling.

  CIP and SIP capability. Full documentation packs and provision of DQ/IQ/OQ.

  Easy to use, sterilize and maintain with low ongoing ownership costs.

Pilot - Production Homogenizing System

Lab scale Homogenizer

Please get in touch to discuss your requirements

Wikipedia. Solid lipid nanoparticles (SLNs). There is only one phospholipid layer because the bulk of the interior of the particle is composed of lipophilic substance. Payloads such as modRNA, RNA vaccine or others can be embedded in the interior, as desired. Optionally, targeting-molecules such as antibodies, cell-targeting peptides, and/or other drug molecules can be bound to the exterior surface of the SLN.

Image copyright: By Andrea Trementozzi - Own work, CC BY-SA 3.0.